Hemolysis testing is a critical biocompatibility evaluation required for medical devices that come into direct or indirect contact with blood, assessing whether device materials or extractables cause damage to red blood cells. This article provides a comprehensive technical overview of hemolysis testing for novel medical devices, covering applicable standards such as ISO 10993-4 and ASTM F756, sample preparation, test methodologies, acceptance criteria, and regulatory considerations for manufacturers seeking market approval.
Technical Overview
Hemolysis testing evaluates the extent to which a medical device or biomaterial damages red blood cells (erythrocytes), releasing hemoglobin into plasma or serum. When blood-contacting devices induce hemolysis beyond acceptable thresholds, patients face serious clinical risks including anemia, hemoglobinemia, hemoglobinuria, renal impairment, and thrombosis. For novel medical devices, hemolysis assessment is therefore a fundamental component of the biological safety evaluation program required by regulators worldwide.
The primary international framework for blood interaction testing is ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), which identifies hemolysis as one of five categories of blood/device interaction: thrombosis, coagulation, platelets, hematology, and the complement system. In the United States, ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials) provides detailed procedures for evaluating material-induced hemolysis. In China, GB/T 16886.4 is the national adoption of the ISO 10993-4 standard and is frequently cited in submissions to the National Medical Products Administration (NMPA).
For novel devices—particularly those with innovative materials, novel surface coatings, complex geometries, or dynamic blood-flow applications—a well-designed hemolysis study must account for both material-mediated and flow-induced (mechanical shear) hemolysis. Static in vitro tests address chemical leachables and surface interactions, while dynamic circulation models simulate physiological flow conditions for devices such as pumps, oxygenators, and heart valve systems.
Testing Samples
Blood-Contacting Medical Devices
Devices categorized under ISO 10993-4 as blood-contacting devices (circulating blood contact, external communicating devices, or implant devices) are the primary candidates for hemolysis evaluation. Typical examples include intravascular catheters, central venous catheters, balloon catheters, drug-eluting stents, vascular grafts, heart valves, vena cava filters, and embolic protection devices.
Extracorporeal Circulation and Blood Handling Equipment
Devices that process, store, or circulate blood outside the body carry elevated hemolysis risk due to prolonged contact and mechanical forces. This category includes hemodialyzers, hemoperfusion cartridges, extracorporeal membrane oxygenation (ECMO) circuits, blood oxygenators, cardiopulmonary bypass tubing sets, autotransfusion systems, infusion sets, transfusion sets, syringes, needles, and blood collection or storage bags.
Biomaterials and Device Components
Raw materials, coatings, adhesives, and surface treatments intended for blood-contacting applications should be characterized individually before device-level testing. Material samples are typically evaluated in extract form to isolate chemical contributions to hemolysis from mechanical effects.
Novel and Combination Products
Emerging device categories such as wearable artificial organs, implantable blood pumps, bioresorbable vascular scaffolds, nanoparticle-based therapeutics, and drug-device combination products may present unique hemocompatibility challenges. For these products, a justified, risk-based test strategy should be documented, often combining standardized static methods with custom dynamic flow rigs that replicate the intended clinical use conditions.
Testing Items
A comprehensive hemolysis evaluation for novel medical devices typically encompasses the following measurements and endpoints:
- Hemolysis Ratio (Hemolysis Index): The percentage of red blood cell lysis calculated from free hemoglobin concentrations in test samples relative to negative and positive controls; a hemolysis ratio of 5% or less is generally regarded as non-hemolytic per ASTM F756.
- Plasma Free Hemoglobin Concentration: Quantified by spectrophotometric methods (commonly at 540 nm or 545 nm) using Drabkin's reagent (cyanmethemoglobin method) or equivalent validated chemistry.
- Direct Contact Hemolysis: Assessment of lysis caused by physical interaction between whole blood and the intact device or material surface.
- Indirect (Extraction) Hemolysis: Assessment of lysis induced by chemical extractables leached from the device under defined extraction conditions (time, temperature, medium, and surface-area-to-volume ratio).
- Dynamic Flow Hemolysis: Evaluation of shear-induced red cell damage under simulated physiological or worst-case flow conditions, with normalized index of hemolysis (NIH) or milligrams of hemoglobin released per 100 liters pumped often reported for circulatory support devices.
- Supplementary Hematological Endpoints: Depending on the risk profile, studies may include complete blood counts, red cell morphology (schistocytes, ghost cells), platelet count, leukocyte count, and coagulation or complement activation markers as part of the broader ISO 10993-4 blood interaction panel.
Testing Methods
Direct Contact Method
In the direct contact assay, anticoagulated rabbit or human blood (typically diluted with phosphate-buffered saline or 0.9% sodium chloride injection) is added to sterile test tubes containing the intact device or cut sections of material. Negative controls (glass beads or physiological saline, depending on the protocol) and positive controls (sterile water for injection or distilled water, which causes complete lysis) are prepared in parallel. After incubation at 37°C for a defined period—commonly two to four hours under static conditions or with gentle rotation—samples are centrifuged, and the absorbance of the supernatant is measured spectrophotometrically at 540 nm or 545 nm to determine free hemoglobin.
Indirect Extraction Method
The extract method evaluates chemically mediated hemolysis. Test articles are extracted in a physiological medium under conditions justified by the device's actual use and extraction parameters specified in ISO 10993-12 (Sample preparation and reference materials). Standard extraction ratios depend on material thickness and device geometry, with common conditions including 37°C for 24 hours or accelerated conditions such as 50°C for 72 hours when scientifically justified. The resulting extract is mixed with diluted whole blood, incubated, centrifuged, and analyzed for released hemoglobin. The hemolysis ratio is calculated as: HR (%) = (OD of test sample − OD of negative control) / (OD of positive control − OD of negative control) × 100.
Dynamic Flow (In Vitro Circulation) Method
For devices whose hemolysis risk is dominated by mechanical shear—blood pumps, ventricular assist devices, ECMO systems, oxygenators, and percutaneous circulatory support devices—a dynamic in vitro recirculation test is performed. Fresh heparinized human or animal blood is circulated through the device in a mock circulatory loop at clinically relevant flow rates and pressures for a specified duration, typically up to six hours. Blood samples are drawn at predetermined intervals, and the normalized index of hemolysis is calculated. This approach, described in ASTM F1847 and related standards as well as FDA guidance for circulatory support devices, enables comparison against predicate benchmarks and supports engineering optimization.
Quality Controls and Method Validity
Each study must include negative and positive controls meeting acceptance criteria. The positive control should produce near-complete hemolysis, the negative control should produce minimal hemolysis, and replicate measurements should demonstrate acceptable precision. Studies are commonly conducted at accredited third-party laboratories or in-house facilities operating under GLP or ISO/IEC 17025 quality systems, with documented method validation covering sample preparation, blood sourcing and handling, incubation parameters, and analytical measurement uncertainty.
Applications
Hemolysis test data support a wide range of regulatory, developmental, and quality objectives across the medical device lifecycle:
- Regulatory Submission: Biological safety documentation for premarket submissions to major regulators—including 510(k) and premarket approval (PMA) applications to the FDA, CE marking technical files under the EU Medical Device Regulation (MDR), and NMPA registration dossiers—routinely requires ISO 10993-4 hemolysis results for blood-contacting devices.
- Novel Material Screening: During research and development, hemolysis assays enable rapid comparison of candidate polymers, metals, ceramics, hydrophilic coatings, and surface modification technologies before committing to expensive device-level testing.
- Design Verification and Iteration: Iterative hemolysis testing guides refinement of geometry, surface finish, and fluid dynamics in blood pumps, oxygenators, and catheter systems to minimize shear stress and stagnation zones.
- Change Control: Changes in raw material suppliers, sterilization method, manufacturing site, or packaging may trigger re-evaluation of hemocompatibility to demonstrate continued biological safety.
- Benchmarking and Equivalence Assessment: Comparative hemolysis data against predicate devices support substantial equivalence arguments and performance claims.
- Quality Monitoring: Periodic hemolysis testing of production lots helps detect process drift or contamination affecting blood compatibility.
FAQ
What is the acceptance criterion for a passing hemolysis test?
Under ASTM F756 and common regulatory expectations, a hemolysis ratio of 5% or less is considered non-hemolytic; values above 5% indicate material or device hemolytic potential requiring mitigation or scientific justification. For dynamic devices such as blood pumps, sponsors should also meet device-specific performance benchmarks defined by the relevant regulatory guidance.
Which standard should novel medical devices follow: ASTM F756 or ISO 10993-4?
ISO 10993-4 defines the overall framework for selecting blood interaction tests based on device category, contact duration, and blood contact nature, while ASTM F756 provides the detailed laboratory procedure for the hemolysis assay itself. In practice, the two standards are complementary, and submissions typically cite both: ISO 10993-4 for the test selection rationale and ASTM F756 (or an equivalent validated in-house method) for execution. In China, GB/T 16886.4 governs the corresponding requirements.
What blood source is used, and how is it anticoagulated?
Rabbit blood anticoagulated with heparin or sodium citrate (often with added calcium chloride to neutralize citrate, depending on the protocol) is traditional, and remains common in ISO 10993-4 based studies. Fresh human donor blood is increasingly preferred, particularly for dynamic testing of cardiovascular devices, because it better represents clinical conditions. Blood must be collected, stored, and used within validated time and temperature limits to avoid pre-test hemolysis artifacts.
How long does a hemolysis study take?
Static direct contact and extract hemolysis assays are typically completed within one to two weeks, including sample preparation, extraction, incubation, and spectrophotometric analysis. Dynamic circulation studies may require longer timelines because of loop setup, blood sourcing logistics, and extended run durations. Overall study duration also depends on sterilization preconditioning, sample scheduling, and report generation at the testing facility.
Can a novel device with a hemolysis ratio above 5% still be approved?
Not automatically disqualified, no—but results above 5% demand action. Manufacturers may redesign the device, modify materials or coatings, adjust surface treatments, or provide a robust toxicological risk assessment demonstrating that the level of hemoglobin release is clinically acceptable for the intended use and patient population. Regulatory reviewers will expect a documented benefit-risk analysis and, where applicable, in vivo or clinical data supporting safety.
Is hemolysis testing sufficient on its own to demonstrate blood compatibility?
No. Hemolysis is only one endpoint within the ISO 10993-4 blood interaction framework. Depending on device category and contact duration, a complete hemocompatibility panel may also include thrombosis testing, coagulation assays (PT, aPTT, thrombin generation), platelet activation and aggregation studies, complement activation (C3a, C5a, SC5b-9), and hematological parameters. Manufacturers of novel devices should develop a justified, risk-based testing plan in consultation with accredited third-party laboratories or regulatory experts early in development.
Do novel surface coatings or drug-eluting features require special hemolysis testing considerations?
Yes. Coatings (such as hydrophilic lubricious coatings, antithrombotic coatings, or drug-eluting layers) can introduce extractables, degradation products, or delamination particles that affect red cell integrity. Test protocols should evaluate the finished, sterilized device in its final form, include extraction conditions that stress the coating appropriately, and consider complementary particulate and cytotoxicity testing to fully characterize blood compatibility.